Antimalarial Compounds Targeting Plasmepsin X and IX Resistance
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current antimalarial treatments face challenges due to increasing drug resistance, necessitating the development of novel compounds that target multiple stages of the Plasmodium life cycle, particularly inhibiting plasmepsin X and IX to block parasite egress and invasion of host cells.
Innovation Solution
Development of compounds of Formula (I) and their pharmaceutically acceptable salts, which inhibit plasmepsin X and/or plasmepsin IX, thereby blocking P. falciparum growth and treating malaria by targeting aspartic acid proteases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If artemisinin-based combination therapy is used to treat malaria, then treatment effectiveness is improved, but drug resistance develops over time
Solution Approach 1:
The patent segments the antimalarial treatment approach by developing compounds that target multiple distinct proteases (plasmepsin IX and plasmepsin X) separately within the parasite's life cycle. This multi-target strategy divides the monotherapy approach into combined inhibition of several enzymatic functions, reducing the likelihood of resistance development through preexisting mutations.
Solution Approach 2:
The patent creates compounds with multi-functionality by designing molecules that can inhibit multiple aspartic acid proteases simultaneously. These compounds serve universal anti-malarial activity against different parasite stages and multiple protease targets, making the treatment more versatile and less prone to resistance compared to single-target therapies.
2Adaptability or versatility
If novel antimalarials targeting multiple life cycle steps are developed, then resistance likelihood is reduced, but drug development complexity increases
Solution Approach 1:
The patent merges the inhibition of multiple protease targets (plasmepsin IX and plasmepsin X) into a single compound design. By combining multiple functional requirements into one molecular structure, the patent achieves multi-stage targeting without requiring separate drugs for each parasite life cycle step, thereby reducing overall treatment complexity while maintaining low resistance likelihood.
Solution Approach 2:
The patent uses aspartic acid protease inhibitors as intermediary molecules that mediate between the host and the parasite's multiple life cycle stages. These compounds act as intermediaries that can simultaneously interfere with invasion, egress, and maturation processes through inhibition of different proteases, simplifying the approach to multi-stage targeting.
3Reliability
If plasmepsin inhibitors are used to block parasite invasion and egress, then parasite maturation is prevented, but drug efficacy against existing infections may be limited
Solution Approach 1:
The patent ensures continuity of useful action by designing compounds that simultaneously inhibit multiple proteases involved in different stages of the parasite life cycle. This continuous multi-target inhibition covers invasion, egress, and maturation processes concurrently, maintaining therapeutic effectiveness throughout the parasite's development and preventing any single stage from proceeding unchecked.
Data Source
AI summary
Provided are methods of treating malaria comprising administration of compounds of Formula (I) or a pharmaceutically acceptable salt thereof, to a subject in need thereof, wherein the variables are as defined herein. Also provided are uses of the compounds of Formula (I), as defined herein, for treating a Plasmodium infection, and for treating malaria. Also provided are methods of treatment further comprising administration of one or more additional anti-malarial compounds.